MD431C2 - Method for leukocytar interferone preparation - Google Patents

Method for leukocytar interferone preparation

Info

Publication number
MD431C2
MD431C2 MD94-0340A MD940340A MD431C2 MD 431 C2 MD431 C2 MD 431C2 MD 940340 A MD940340 A MD 940340A MD 431 C2 MD431 C2 MD 431C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
hc1f
interferone
preparation
Prior art date
Application number
MD94-0340A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Weissman Charles
Original Assignee
Biogen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8187070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD431(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc filed Critical Biogen, Inc
Publication of MD431C2 publication Critical patent/MD431C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y10S435/839—Bacillus subtilis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Utilization: genetic engineering, leukocitar interferone preparation. Summary: the method includes detection and separation of DNA sequence of and formation recombinante DNA molecules which possess immunologic and biologic activity of IFNU-α. There are obtained the recombinate plasmidic DNA sequence containing the DNA sequences of Z-pBR 322 (Pst) HCIF-4c, Z-pBR 322 (Pst), HIF-2h, Z-pBR 322 (Pst) Hc1F-SN-35, Z-pBR 322 (Pst) Hc1F-SN-42, Z-pKT287 (Pst) Hc1F-2h-AH6, as well as sequences, which are hybridized with the mentioned insertions.
MD94-0340A 1980-01-08 1994-10-17 Method for leukocytar interferone preparation MD431C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP80300079 1980-01-08

Publications (1)

Publication Number Publication Date
MD431C2 true MD431C2 (en) 1996-07-31

Family

ID=8187070

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0340A MD431C2 (en) 1980-01-08 1994-10-17 Method for leukocytar interferone preparation

Country Status (7)

Country Link
US (1) US4530901A (en)
JP (2) JPS56150100A (en)
IN (1) IN153751B (en)
MD (1) MD431C2 (en)
SU (1) SU1764515A3 (en)
UA (1) UA13380A (en)
ZA (1) ZA81103B (en)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
DE3176011D1 (en) * 1980-06-12 1987-04-23 Japan Found Cancer Plasmid
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4810645A (en) * 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5399684A (en) * 1982-05-20 1995-03-21 Washington Research Foundation DNA sequences expressing mammalian alpha-1-antitrypsin
DE3220116A1 (en) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF
JPS60222500A (en) * 1983-12-19 1985-11-07 シエリング・コ−ポレ−シヨン Novel hybrid interferon
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
SU1364343A1 (en) * 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Method of producing manъs leukocytic interferon alfa-2
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US4874743A (en) * 1985-01-10 1989-10-17 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
US5081019A (en) * 1985-01-10 1992-01-14 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
US4950646A (en) * 1985-01-10 1990-08-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
US4879224A (en) * 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
WO1986004608A1 (en) * 1985-02-05 1986-08-14 Synergen Biologicals, Inc. Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant-dna method for the manufacture of same
JPS61185189A (en) * 1985-02-08 1986-08-18 Green Cross Corp:The Dna sequence of novel interferon-alpha1, recombinant plasmid and transformation
US4894332A (en) * 1985-03-27 1990-01-16 Biogen, Inc. DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
US6774283B1 (en) 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DK402785D0 (en) * 1985-09-03 1985-09-03 Syn Tek Ab PROCEDURE FOR THE PREPARATION OF AN ENZYM
US5135868A (en) * 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5089406A (en) * 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
JPH01503513A (en) * 1987-03-02 1989-11-30 オンコゲン Platelet-related growth regulator
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
EP0330396B1 (en) * 1988-02-26 1995-06-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI
US5605815A (en) * 1988-03-14 1997-02-25 Yale University Nucleic acids encoding and expression of parathyroid hormone-like peptide
JPH03503844A (en) * 1988-04-15 1991-08-29 リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド LAK cell cytotoxin
DK455789D0 (en) * 1989-09-15 1989-09-15 Symbicom Ab POLYPEPTIDE
JP2772062B2 (en) * 1989-09-26 1998-07-02 株式会社ニッコー Direction changing device for traveling toys
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
HUT65827A (en) * 1990-04-02 1994-07-28 Synergen Inc Polypeptides useful in animal treatment against mycoplasma infections
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
JP2649317B2 (en) * 1993-10-25 1997-09-03 株式会社キジマ Glove manufacturing method
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (en) 1995-11-02 2004-09-16 Schering Corporation CONTINUOUS INFUSION THERAPY OF CITOCINES AT LOW DOSE.
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
JP2001523480A (en) 1997-11-20 2001-11-27 バイカル インコーポレイテッド Treatment of cancer with cytokine-expressed polynucleotides and their compositions
DE69901321T2 (en) 1998-05-15 2002-12-12 Schering Corp., Kenilworth Combination therapy containing ribavirin and interferon alpha in patients with chronic hepatitis C infection who have not been previously treated with antiviral drugs
ATE403728T1 (en) * 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd ATTENUATED SALMONELLA SPI2 MUTANT AS ANTIGEN CARRIER
DK1894944T3 (en) 1998-11-12 2010-10-18 Schering Corp Methods for converting interferon isoforms and products thereof
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
EP1535622B1 (en) 1999-04-08 2008-12-31 Schering Corporation Melanoma therapy
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2306771T3 (en) * 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc A CELLULAR THERAPY METHOD FOR TUMOR TREATMENT.
CN1247258C (en) 2001-04-24 2006-03-29 默克专利有限公司 Combination therapy using anti-angiogenic agents and tnfa
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
BRPI0415771A (en) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detection of mutations in a gene associated with resistance to viral infection, oas1
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
BRPI0507169A (en) 2004-02-02 2007-06-26 Ambrx Inc modified human growth hormone polypeptides and their uses
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
GB0514661D0 (en) * 2005-07-16 2005-08-24 Medical Res Council Methods
DE602005020046D1 (en) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-associated peptides that bind to different human leukocyte antigens of class II
SI1760089T1 (en) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2021791A2 (en) * 2006-05-31 2009-02-11 Unilever N.V. Method of screening for compounds that alter skin and/or hair pigmentation
EP2474318A1 (en) * 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
HUE025636T2 (en) 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
RS54204B1 (en) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20100249373A1 (en) * 2007-11-27 2010-09-30 Richard Martin Ogborne Screening methods
ME02267B (en) 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunotherapy against nerve and brain tumors
PT2119726E (en) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii peptides derived from survivin and neurocan
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
ES2536465T3 (en) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composition of tumor-associated and cancer-related peptides for the treatment of glioblastoma (GBM) and other cancers
WO2010040063A1 (en) * 2008-10-03 2010-04-08 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of hepatitis c infection with metalloporphyrins
ES2342529B1 (en) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. ONCOSTATINA M AS POTENTIATOR OF THE IMMUNOSTIMULATING ACTIVITY OF HUMAN EPITHELIAL CELLS.
US20110257368A1 (en) 2008-12-23 2011-10-20 Schering Corporation Purification of recombinantly produced interferon
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
JP5576928B2 (en) 2009-03-27 2014-08-20 ジェイダブリュ ファーマシューティカル コーポレーション IFN-α fusion protein comprising interferon-alpha and cytoplasmic residual cell membrane penetrating peptide
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
JP5794532B2 (en) * 2009-10-16 2015-10-14 学校法人立命館 Interferon-α modulator
KR20120106942A (en) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
RS55348B1 (en) 2010-04-19 2017-03-31 Oryzon Gnomics S A LYSINE INHIBITORS SPECIFIC DEMETHYLASE-1 AND THEIR USE
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (en) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
BR112014010295A2 (en) 2011-10-31 2017-04-18 Gilead Pharmassett Llc methods and compositions for the treatment of hepatitis c virus
SG11201402609RA (en) 2011-11-29 2014-06-27 Gilead Pharmasset Llc Compositions and methods for treating hepatitis c virus
JP2015509980A (en) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
US9624527B2 (en) 2013-03-01 2017-04-18 Boehringer Ingelheim Vetmedica, Inc. Quantification of vaccine compositions
WO2014197400A1 (en) 2013-06-04 2014-12-11 Gilead Pharmasset Llc Preventing and treating recurrence of hcv infection after liver transplant
TWI714869B (en) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP4012049A3 (en) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to mek/erk inhibitors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (en) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (en) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF ESOPHAGUS CANCER AND OTHER CANCERS
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
PE20181583A1 (en) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh RECOMBINANT PEPTIDE DERIVED FROM THE DUOXA2 PROTEIN
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP4357454A3 (en) 2016-03-16 2024-07-24 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20221375T1 (en) 2016-03-16 2023-01-06 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (en) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TW201841937A (en) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 Novel peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CR20210160A (en) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER (DIVISIONAL APPLICATION 2019-0508)
TW201841934A (en) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 Novel peptides and peptide compositions thereof for treating cancer immunotherapy
KR20200026898A (en) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Novel peptides and combinations of peptides for use in immunotherapy against lung and other cancers such as NSCLC, SCLC
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
DE102018107224A1 (en) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers
TW202016131A (en) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 Peptides for use in immunotherapy against cancers
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (en) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (en) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
TW202039535A (en) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
DE102020125457A1 (en) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer
TW202229312A (en) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
TW202241925A (en) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 Peptides displayed by hla for use in immunotherapy against different types of cancers
EP4761754A2 (en) 2023-08-18 2026-06-24 Immatics Biotechnologies GmbH Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699222A (en) * 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
GB1521032A (en) * 1974-08-08 1978-08-09 Ici Ltd Biological treatment
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
DE2724918A1 (en) * 1977-06-02 1978-12-14 Thomae Gmbh Dr K Antiviral and antitumour human interferon prodn. - by incubating virus-infected namalva cells on serum-free medium
ZA782933B (en) * 1977-09-23 1979-05-30 Univ California Purification of nucleotide sequences suitable for expression in bacteria
FR2422956A1 (en) * 1978-04-13 1979-11-09 Pasteur Institut METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS
JPS5519239A (en) * 1978-07-28 1980-02-09 Green Cross Corp:The Interferon-producing attractant
FI792481A7 (en) * 1978-08-11 1981-01-01 The Regents Of The Univ Of Enkaryotic protein synthesis using a microorganism.
GB2033905B (en) * 1978-08-21 1982-10-13 Upjohn Co Bacterial preparation of proteins
JPS5561798A (en) * 1978-10-30 1980-05-09 Noda Sangyo Kagaku Kenkyusho Preparation of novel recombination dna
FR2440957A1 (en) * 1978-11-13 1980-06-06 Pasteur Institut VECTORS SUITABLE FOR INSERTION INTO THEIR GENOMES OF FOREIGN DNA FRAGMENTS, ACCORDING TO ANY OF THE POSSIBLE TRANSLATION PHASES, AND MEANS FOR THEIR MANUFACTURE
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4241174A (en) * 1978-11-24 1980-12-23 Hoffmann-La Roche Inc. Interferon assay
FR2444713A1 (en) * 1978-12-18 1980-07-18 Pasteur Institut PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME
FI77877C (en) * 1979-04-20 1989-05-10 Technobiotic Ltd Process for the preparation and purification of human Le-shaped interferon protein.
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
US4262090A (en) * 1979-06-04 1981-04-14 Cetus Corporation Interferon production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Natl. Acad. Sci., USA 76, p. 640-644, 1979. *

Also Published As

Publication number Publication date
UA13380A (en) 1997-02-28
JPH0321151B2 (en) 1991-03-22
JPH0321150B2 (en) 1991-03-22
JPS56150100A (en) 1981-11-20
ZA81103B (en) 1982-01-27
JPS62122590A (en) 1987-06-03
SU1764515A3 (en) 1992-09-23
IN153751B (en) 1984-08-18
US4530901A (en) 1985-07-23

Similar Documents

Publication Publication Date Title
AU9058091A (en) Preparation of nucleic acid samples
DE3689195D1 (en) Process for the production of aloe products, products and compositions therefor.
ES2009286A6 (en) Transcription-based nucleic acid amplification/detection systems.
YU55683A (en) Process for expressiation, altering and excreting heterologic proteine by using yeast
AR243966A1 (en) Process for increasing the degree of petroleum extraction.
DE3689196D1 (en) Process for the preparation of amides using microorganisms.
DE3586697D1 (en) Aktive thymopentin-analoga.
EP0165033A3 (en) Conformationally restricted thymopentin-like compounds
DK54184D0 (en) DNA SEQUENCES, RECOMBINATION DNA MOLECULES, AND METHODS FOR HUMAN PREPARATION (INTERLEUKIN) TWO SIMILAR POLIPEPTIDES
ZA862334B (en) Process for amplifying,detecting and/or cloning nucleic acid sequences
WO1992020796A3 (en) D-type cyclin and uses related thereto
MY101184A (en) Method for the separation of oil-in water emulsions.
ATE104338T1 (en) IMPROVED NUCLEIC ACID ISOLATION AND CONCENTRATION COMPOSITION AND THEREFORE IMPROVED PROCESS.
DE3577560D1 (en) SILICON OXYDE-BASED, ETHER-BONDED STABLE PHASES FOR THE SEPARATION OF BIOPOLYMERS.
DE3677401D1 (en) METHOD FOR THE PRODUCTION OF PERYLENE-3,4,9,10-TETRACARBONIC ACIDARYLIMIDES.
FI872659A7 (en) Method for the preparation of novel androst-4-ene-3,17-diones.
ATE74007T1 (en) IMMUNE ENHANCERS AND PROCESSES FOR THEIR PRODUCTION.
DE3577372D1 (en) METHOD FOR THE PRODUCTION OF SUN CELLS FROM AMORPHEMIC SILICON AND THE PRODUCT PRODUCED BY IT.
AU4671685A (en) Separation process with recovery of proteins & fats from substances of animal origin, organic substances or refluent from working organic substances & plant to carry out the
DE3581958D1 (en) METHOD FOR PRODUCING N-ACETYLNEURAMINATE LYASE.
IT8567141A1 (en) Procedure for cell culture, by means of gas dispersion.
ATE73847T1 (en) DNA FRAGMENT WITH THE CYCLODEXTRIN GLYCOSYLTRANSFERASE STRUCTURAL GENE, EXPRESSION VECTOR, EXPRESSION MICROORGANISMS AND METHOD OF MANUFACTURE.
EP0076696A3 (en) A restriction enzyme and a method for production thereof
HUT46077A (en) Process for the microbiological production of 9alpha-hydroxy-4-androsten-3,17-dione
ES8602123A1 (en) Yeast copper-metallothionein gene.